News

Mercury Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.

Net profit of Mercury Laboratories rose 10.81% to Rs 1.23 crore in the quarter ended March 2026 as against Rs 1.11 crore during the previous quarter ended March 2025. Sales declined 1.06% to Rs 20.44 crore in the quarter ended March 2026 as against Rs 20.66 crore during the previous quarter ended March 2025.For the full year,net profit rose 53.82% to Rs 4.83 crore in the year ended March 2026 as against Rs 3.14 crore during the previous year ended March 2025. Sales rose 1.12% to Rs 75.94 crore in the year ended March 2026 as against Rs 75.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales20.4420.66 -1 75.9475.10 1 OPM %9.9810.31 -11.889.35 - PBDT2.582.18 18 10.447.54 38 PBT1.741.45 20 7.024.66 51 NP1.231.11 11 4.833.14 54 Powered by Capital Market - Live News

Mercury Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Net profit of Mercury Laboratories declined 15.97% to Rs 1.00 crore in the quarter ended December 2025 as against Rs 1.19 crore during the previous quarter ended December 2024. Sales declined 6.23% to Rs 18.35 crore in the quarter ended December 2025 as against Rs 19.57 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales18.3519.57 -6 OPM %13.7910.12 - PBDT2.702.38 13 PBT1.831.64 12 NP1.001.19 -16 Powered by Capital Market - Live News

Mercury Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live News